Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 1296-1304, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-969790
ABSTRACT
Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors are anti-tumor agents for the treatment of hormone receptor-positive breast cancer. Palbociclib, abemaciclib and dalpiciclib have been approved for the treatment of breast cancer in China. Common adverse effects of CDK4/6 inhibitors include bone marrow suppression, gastrointestinal toxicities, liver dysfunction, and skin or subcutaneous tissue adverse reactions (AEs). The Breast Cancer Expert Group of Chinese Society of Clinical Oncology (CSCO) summarized the incidence, clinical manifestations, and grading of the AEs. This expert consensus reports measures of AE management on the basis of experience of clinical practice and the latest advances worldwide, aiming to guide clinical practice by the way of managing AE and help to choose the best treatment regimen.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Breast Neoplasms
/
Consensus
/
Protein Kinase Inhibitors
/
Cyclin-Dependent Kinase 4
/
Cyclin-Dependent Kinase 6
/
Aminopyridines
/
Antineoplastic Agents
Limits:
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS